Business
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
LARGO, Fla., December 05, 2025--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair.
About this update from Conmed Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1518,"height":285,"url":"https://media.zenfs.com/en/business-wire.com/888b7dd85533744cb31d3af46fce83ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JrCMSBF8zy7UqlHWQmtOPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/888b7dd85533744cb31d3af46fce83ed","width":960,"height":180},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XGlO6h6ZsyUo9.kdS_rc2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/888b7dd85533744cb31d3af46fce83ed","width":1200,"height":225}},"lazy":false},{"type":"text","content":"Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January 1, 2026","length":114,"tagName":"p","attribs":{}},{"type":"text","content":"Announces Intent to Exit Remaining Products in its Gastroenterology Product Portfolio","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"Reaffirms 2025 Revenue and EPS Guidance","length":39,"tagName":"p","attribs":{}},{"type":"text","content":"LARGO, Fla., December 05, 2025--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair.","length":431,"tagName":"p"},{"type":"text","content":""Today’s announcement reflects a positive step in our strategic portfolio review and our commitment to focus on areas where CONMED can lead in innovation and deliver the greatest impact— minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair," said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. "By concentrating our resources on our core growth platforms, we are positioning CONMED for long-term success and continued leadership in surgical innovation. We are proud of the contributions our gastroenterology team has made to advancing patient care and supporting clinicians over the years, and we thank them for their dedication and im...